Curcumin: A boon to colonic diseases

Current Drug Targets

Volumn 14, Issue 10, 2013, Pages 1210-1218

  Sareen, Rashmi ^a   Jain, Nitin ^a   Pandit, Vinay ^b  

^a SHOOLINI UNIVERSITY   (India)

^b AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

Approaches; Clinical studies; Colon cancer; Curcumin; Inflammatory bowel disease; Turmeric

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BETA CYCLODEXTRIN; CURCUMA EXTRACT; CURCUMIN; CYCLIN D1; CYCLODEXTRIN; CYCLOOXYGENASE 2; GAMMA INTERFERON; GELATINASE B; GLUTATHIONE; GLUTATHIONE TRANSFERASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; MALONALDEHYDE; MESALAZINE; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NANOPARTICLE; P54FP; PHOSPHOLIPID; PIPERINE; PLANT EXTRACT; POLYMER; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; COLON DISEASE; COLORECTAL CANCER; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; MICELLE; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; COLONIC DISEASES; CURCUMIN; DRUG DELIVERY SYSTEMS; HUMANS; SIGNAL TRANSDUCTION;

EID: 84881361511     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990168     Document Type: Review

References (82)

1. Shen L, Ji HF. The pharmacology of curcumin: is it the degradation products. Trends in Mol Med 2012; 18(3): 138-144.
2. Karewicz A, Bielska D, Gzyl-Malcher B, Kepczynski M, Lach R, Nowakowska M. Interaction of curcumin with lipid monolayers and liposomal bilayers. Colloids Surf B Biointerfaces 2011; 88: 231-9.
3. Zhou H, Beevers CS, Huanq S. The targets of curcumin. Curr Drug Targets 2011; 12(3): 332-47.
4. Setthacheewakul S, Mahattanadul S, Phadoongsombut N, Pichayakorn W, Wiwattanapatapee R. Development and evaluation of selfmicroemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur J Pharm Biopham 2010; 76: 475-85.
5. Srivastava RM, Singh S, Dubey SK, Misra K, Khar A. Immunomodulatory and therapeutic activity of curcumin. Int Immunopharmacol 2011; 11: 331-41
6. Yadav VR, Prasad S, Kannappan R, et al. Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem. Pharmacol 2010; 80: 1021-32.
7. Watson JL, Hill R, Yaffe PB, Greenshields A, Walsh M, Lee PW, Giacomantonio CA, Hoskin DW. Curcumin causes superoxide anion production and p53-independent apoptosis in human colon cancer cells. Cancer Letters 2010; 297: 1-8.
8. Hartmann G, Bidlingmaier C, Siegmund B, et al. Specific type IV phosphordiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol ExpTher 2000; 292: 22-30.
9. Klein SJ, Stein J, Dressman J. Site-specific delivery of antiinflammatory drugs in the gastrointestinal tract: an in-vitro release model. J Pharm Pharmacol 2005; 57: 709-19.
10. Dhar A. Environmental factors associated with Crohn's disease in India-there's more to it than meets the eye. Indian J Gastroenterol 2011; 30(6): 255-6.
11. Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia- Pacific area: A comparison with developed countries and regional differences. J Dig Dis 2010; 11: 134-47.
12. Javid G, Zargar SA, Rather S, et al. Incidence of colorectal cancer in Kashmir valley, India. Indian J Gastroenterol 2011; 30(1): 7-11.
13. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363-98.
14. Wilken, R Veena MS, Wang MB, Srivatsan ES. Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 2011; 10: 12.
15. Vogel HA, Pelletier J. Curcumin-biological and medicinal properties. J Pharma 1815; 2: 50.
16. Milobedzka J, Kostanecki V, Lampe V. Structure of curcumin. Ber Dtsch Chem Ges 1910; 43: 2163-2170.
17. Roughley PJ, Whiting DA. Experiments in the biosynthesis of curcumin. J ChemSoc Perkin Trans 1973; 20: 2379-2388.
18. Payton F, Sandusky P, Alworth WL. NMR study of the solution structure of curcumin. J Nat Prod 2007; 70: 143-6.
19. Aggarwal BB, Surh YJ, Shishodia S. Eds. Advances in experimental medicine and biology. In The Molecular Target and Therapeutic Uses of Curcumin in Health and Disease, Springer: New York, NY, USA, 2007.
20. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research. Altern Med Rev 2009; 14 (2): 141-53.
21. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow. Lancet 2001; 357: 539-45.
22. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
23. Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: Progress and promise. Antioxid Redox Signal 2008; 10: 475-510.
24. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397-1421.
25. Biesalski HK. Polyphenols and inflammation: Basic interactions. Curr Opin Clin Nutr Metab Care 2007; 10: 724-8.
26. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Letters 2007; 255: 170-81.
27. SreejayanRao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 1994; 46: 1013-6.
28. Masuda T, Maekawa T, Hidaka K, Bando H, Takeda Y, Yamaguchi H. Chemical studies on antioxidant mechanisms of curcumin: analysis of oxidative coupling products from curcumin and linoleate. J Agric Food Chem 2001; 49: 2539-47.
29. Shoskes D, Lapierre C, Cruz-Correa M, Muruve N, Rosario R, Fromkin B, Braun M, Copley J. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: A randomized placebo controlled trial. Transplantation 2005; 80: 1556-9.
30. Joosten SA, Sijpkens YW, Van Kooten C, Paul LC. Chronic renal allograft rejection: Pathophysiologic considerations. Kidney Int 2005; 68: 1-13.
31. Shaikewitz ST, Chan L. Chronic renal transplant rejection. Am J Kidney Dis 1994; 23: 884-893.
32. Avihingsanon Y, Ma N, Csizmadia E, et al. Expression of protective genes in human renal allografts: A regulatory response to injury associated with graft rejection. Transplantation 2002; 73: 1079-85.
33. Durgaprasad S, Ganesh Pai C, VasanthkumarAlvres JF, Sanjeeva N. A pilot study of the anti-oxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 2005; 122: 315-8.
34. Handler N, Jaeger W, Puschacher H, Leisser K, Erker T. Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors. Chem Pharm Bull 2007; 55: 64-71.
35. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-B and I B[1] kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053-62.
36. Ireson CR, Orr S, Jones DJ, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 2001; 61: 1058-64.
37. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: A pilot study. Dig Dis Sci 2005; 50: 2191-3.
38. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 1502-6.
39. Satoskar RR, Shah SJ, Shenoy SG. Evaluation of antiinflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 1986; 24: 651-4.
40. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980; 71: 632-4.
41. Lal B, Kapoor AK, Asthana OP, Agrawal PK, Prasad R, Kumar P, Srimal RC. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res1999; 13: 318-22.
42. Schallreuter KU, Rokos H. Turmeric (curcumin): A widely used curry ingredient, can contribute to oxidative stress in Asian patients with acute vitiligo. Indian J Dermatol Venereol Leprol 2006; 72: 57-59.
43. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005; 50(11): 2191-3.
44. Carroll RE, Benya RV, Turgeon DK, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 2011; 4(3): 354-64.
45. Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005; 14(1): 120-5.
46. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7: 1894-900.
47. Ireson CR, Jones DJ, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002; 11: 105-11.
48. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 2001; 21: 2895-900.
49. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847-54.
50. Irving GRB, Karmokar A, Berry DP, Brown K, Steward WP. Curcumin: The potential for efficacy in gastrointestinal diseases. Best Pract Res Clin Gastroenterol 2011; 25: 519-34.
51. Shpitz B, Giladi N, Sagiv E, et al. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 2006; 74(3-4): 140-4.
52. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 2001; 21(4B): 2895-900.
53. Garcea G, Jones DJ, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004; 90(5): 1011-5.
54. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010; 62(8): 1137-41.
55. Braumann C, Guenther N, Loeffler LM, Dubiel W. Liver metastases after colonic carcinoma - palliative chemotherapy plus curcumin. Int J Colorectal Dis 2009; 24(7): 859-60.
56. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 15; 10(20): 6847-54.
57. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 2007; 595: 453-70.
58. Basu NK, Kole L, Kubota S, Owens IS. Human UDP glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Dispos 2004; 32: 768-773.
59. Sugiyama Y, Kawakishi S, Osawa T. Involvement of the betadiketone moiety in the antioxidative mechanism of tetrahydro curcumin. Biochem Pharmacol 1996; 52: 519-25.
60. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling and angiogenesis. Cancer 2005; 104: 1322-31.
61. Kumar V, Lewis SA, Mutalik S, Shenoy DB, Udupa N. Biodegradable microspheres of curcumin for treatment of inflammation. Indian J Physiol Pharmacol 2002; 46: 209-17.
62. Han G, Xu J, Li W, Ning C. Study on preparation of the inclusion compound of curcumin with beta-cyclodextrin. Zhong Yao Cai 2004; 27: 946-8.
63. Bhawana, Basniwal RK, Buttar HS, Jain VK, Jain N. Curcumin nanoparticles: preparation, characterization, and antimicrobial study. J Agric Food Chem 2011; 59: 2056-2061.
64. Gao Y, Li Z, Sun M, et al. Preparation and characterization of intravenously injectable curcumin nanosuspension. Drug Deliv 2011; 18: 131-42.
65. Tsai YM, Jan WC, Chien CF, Lee WC, Lin LC, Tsai TH. Optimized nano-formulation on the bioavailability of hydrophobic polyphenol, curcumin, in freely-moving rats. Food Chem 2011; 127: 918-25.
66. Anitha, A, Deepagan VG, Divya Rani VV, Menon D, Nair SV, Jayakumar R. Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphatechitosan nanoparticles. Carbohyd Polym 2011; 84: 1158-64.
67. Shaikh J, Ankola DD, Beniwal V, Singh D, Ravi Kumar MNV. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009; 37: 223-30.
68. Wang X, Jiang Y, Wang YW, Huang MT, Ho CT, Huang Q. Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions. Food Chem 2008; 108: 419-24.
69. Anjana D, Nair KA, Somashekara N, et al. Development of curcumin based ophthalmic preparation. American J Inf Diseases 2012; 8(1): 41-9.
70. Joshi RP, Negi G, Kumar A, et al. SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: An insight into its mechanism for neuroprotection. Nanomedicine 2013; pii: S1549-9634(13)00006-3.
71. Basnet P, Basnet NS. Curcumin: An Anti-Inflammatory Molecule from a Curry Spice on the Path to Cancer Treatment. Molecules 2011; 16: 4567-98
72. Gupta NK, Dixit VK. Bioavailability enhancement of curcumin by complexation with phosphatidylcholine. J Pharm Sci 2011; 100: 1987-95.
73. Yadav VR, Suresh S, Devi K, Yadav S. Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and antiinflammatory activity for optimization of therapy of inflammatory bowel disease. J Pharm Pharmacol 2009; 61: 311-21.
74. Li L, Ahmed B, Mehta K, Kurzrock R. Liposomal curcumin with and without oxaliplatin: Effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol. Cancer Ther 2007; 6: 1276-82.
75. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 2008; 32: 1119-23.
76. Takahashi M, Inafuku K, Miyagi T, Oku H, Wada K, Imura T, Kitamoto D. Efficient preparation of liposomes encapsulating food materials using lecithins by a mechanochemical method. J Oleo Sci 2007; 56: 35-42.
77. Bansal SS, Vadhanam MV, Gupta RC. Development and in vitro-in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin. Pharm. Res. 2011; 28: 1121-30.
78. Bansal SS, Kausar H, Vadhanam MV, Ravoori S, Gupta RC. Controlled systemic delivery by polymeric implants enhances tissue and plasma curcumin levels compared with oral administration. Eur J Pharm Biopharm 2012; 80: 571-7.
79. Ma Z, Haddadi A, Molavi O, Lavasanifar A, Lai R, Samuel J. Micelles of poly(ethylene oxide)-b-poly([1]-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J Biomed Materials Res Part A 2008; 86(A): 300-10.
80. Song Z, Feng R, Sun M, et al. Curcumin-loaded PLGA-PEGPLGA triblockcopolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 2011; 354: 116-23.
81. Mohan PRK, Sreelakshmi G, Muraleedharan CV, Joseph R. Water soluble complexes of curcumin with cyclodextrins: Characterization by FT-Raman spectroscopy. Vibrational Spectroscopy 2012; 62: 77-84.
82. Michel D, Chitanda JM, Balogh R, et al. Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly soluble curcumin analogs for the treatment of melanoma. Eur J Pharm Biopharm 2012; 81(3): 548-56.